We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The EU’s dispute with AstraZeneca (AZ) over the supply of the company’s vaccine intensified yesterday as European Commission (EC) officials met with the company and called on it to release the full terms of its European supply contract. Read More
A new study has found that Eli Lilly and Regeneron may need to adjust their monoclonal antibody treatments to effectively fight fast-spreading COVID-19 variants, especially the South African mutation, which along with a UK variant has raised concerns among scientists that SARS-CoV-2 may mutate to resist vaccines and treatments. Read More
Emergent Biosolutions has entered into an agreement to manufacture Humanigen’s lenzilumab, a potential treatment for COVID-19, ahead of an emergency use filing expected early this year. Read More
In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine. Read More
President Biden yesterday revived a travel ban aimed at preventing the mutated strain of SARS-CoV-2 coronavirus first detected in South Africa from reaching the U.S. — and Moderna said it will launch a trial to evaluate a booster shot meant to provide additional protection against the mutated strain. Read More
Anthony Fauci, the leading U.S. authority on infectious diseases, has cautioned against putting off second doses of Pfizer/BioNTech’s and Moderna’s vaccines to accelerate initial vaccinations, a strategy the UK is currently using and one President Biden has said he will adopt as vaccine makers experience delays in vaccine shipments. Read More
In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. Read More
Pfizer and BioNTech have struck a supply deal with the World Health Organization (WHO)-backed COVAX program, pledging to ship up to 40 million doses of their COVID-19 vaccine this year for an undisclosed price. Read More